An FDA advisory committee voted that a pair of chimeric antigen receptor T-cell therapies should be approved for earlier line treatments in adults with relapsed or refractory multiple myeloma, although one produced far more deliberation.
The committee determined the PFS benefits of ciltacabtagene autoleucel (Carvykti; Janssen, Legend Biotech) and idecabtagene vicleucel (Abecma, Bristol Myers Squibb) both outweigh data regarding risks for early death in treatment.
The panel voted unanimously to recommend earlier use of ciltacabtagene autoleucel, also called cilta-cel, and 8-3 to advise for
